Acotec Scientific Holdings (HKSE:06669) EBIT per Share : HK$0.09 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings EBIT per Share?

Acotec Scientific Holdings's EBIT per Share for the six months ended in Dec. 2023 was HK$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Acotec Scientific Holdings's EBIT per Share or its related term are showing as below:

HKSE:06669's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Acotec Scientific Holdings's EBIT for the six months ended in Dec. 2023 was HK$-2.5 Mil.

Acotec Scientific Holdings EBIT per Share Historical Data

The historical data trend for Acotec Scientific Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings EBIT per Share Chart

Acotec Scientific Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

0.10

-0.11

-0.31

0.27

0.09

Acotec Scientific Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial				-0.29	0.12	0.15	0.10	-0.01

Acotec Scientific Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Acotec Scientific Holdings's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	26.562	/	301.078
=	0.09

Acotec Scientific Holdings's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.514	/	301.266
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.09

Acotec Scientific Holdings (HKSE:06669) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Acotec Scientific Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acotec Scientific Holdings (HKSE:06669) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

7W3:Germany

Address

16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN

Website

http://www.acotec.cn

Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.

Executives

Vistra Trust (singapore) Pte. Limited	2301 Trustee
Nexus Partners Group Limited	2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited	2101 Beneficial owner
Li Jing	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited	2101 Beneficial owner
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpe Gof Gp Limited	2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p.	2201 Interest of corporation controlled by you
Boston Scientific Corporation	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines